Chairpersons: Catharina Boehme, FIND, and Daniela Cirillo, San Raffaele Scientific Institute, NDWG Co-Chairs


Session 1: The global TB diagnostics pipeline: Progress and needs

- Welcome address, Catharina Boehme and Daniela Cirillo
Overview and updates on recent developments against needs, Claudia Denkinger, FIND
The funding gap in TB diagnostics R&D - Results from report on TB research funding trends, Erica Lessem, TAG
Use of genome-wide expression for diagnosing active TB and potential for non-sputum based diagnosis, Purvesh Khatri, Stanford University
Potential of cell-free DNA in plasma or urine for rapid detection of Mycobacterium tuberculosis, Niaz Banaei, Stanford University

Session 2: Supporting development of new tests for LTBI: Recent advances

Incipient TB assays to support TB elimination: Opportunities and challenges, Samuel Schumacher, FIND
Estimating the impact of a test for incipient TB: Preliminary results of a transmission and cost effectiveness model, Suzanne Verver, Erasmus University Medical Center
- The current landscape of discovery and early development in LTBI and incipient TB, Gavin Churchyard, Aurum Institute (Presentation not available)

Session 3: Progress in the use of next-generation sequencing (NGS) for surveillance, diagnosis and patient management

Programmatic Implementation of NGS for TB and future plans for the ReSeqTB knowledgebase Timothy Rodwell, FIND / UCSD
- Predicting susceptibility to first-line drugs: Can we phase out phenotypic DST and transition to WGS-led diagnostics? Timothy Walker, University of Oxford (Presentation will be available later)
WHO policy update: Interpretation of DST Christopher Gilpin, World Health Organization

Session 4: Panel discussion: Challenges in molecular testing roll-out on a programmatic level

Introduction by the Moderator: Martina Casenghi, Core Group New Diagnostics Working Group

Speakers bios